Overview

Study to Evaluate Three Times Per Week (TIW) Oral Dosing of Vadadustat for Anemia in Subjects With Dialysis-Dependent Chronic Kidney Disease (DD-CKD)

Status:
Withdrawn

Trial end date:
2018-02-12

Target enrollment:

Participant gender:

Summary

This is a Phase 3 Study to Evaluate Three Times Per Week (TIW) Oral Dosing of Vadadustat for Anemia in Subjects with Dialysis-Dependent Chronic Kidney Disease (DD-CKD)

Phase:

Phase 3

Details

Lead Sponsor:

Akebia Therapeutics

Treatments:

Darbepoetin alfa